CADTH | Evidence Driven
CADTH | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Xarelto Rivaroxaban Venous thromboembolic events, pulmonary embolism List with criteria/condition Complete
Eliquis Apixaban Venous thromboembolic events, treatment and prevention of recurrence List with clinical criteria and/or conditions Complete
Xarelto Rivaroxaban Venous thromboembolism, prevention N/A Complete
Lixiana VTE Edoxaban Venous thromboembolism, treatment and recurrence prevention. Reimburse with clinical criteria and/or conditions Complete
Luxturna voretigene neparvovec Vision loss, inherited retinal dystrophy Reimburse with clinical criteria and/or conditions Complete
Jetrea Ocriplasmin Vitreomacular adhesion List with criteria/condition Complete
Welireg belzutifan von Hippel-Lindau disease-associated tumours Reimburse with clinical criteria and/or conditions Complete
Vonvendi von Willebrand Factor [recombinant] von Willebrand disease, adults, treatment and perioperative management Reimburse with clinical criteria and/or conditions Complete
Imbruvica Ibrutinib Waldenstrom's Macroglobulinemia Do not reimburse Complete
Imbruvica ibrutinib Waldenström’s Macroglobulinemia Reimburse with clinical criteria and/or conditions Complete
Last Updated : April 27, 2024